The LLS Blog
Read about survivors, research, fundraising and advocacy.
FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma
Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Honoring My Daughter’s Legacy By Continuing Her Fight
Today is International Childhood Cancer Day, a day that had little significance for me less than four short years ago. In October 2017, I heard the words, “Your child has cancer,” which I soon learned could only be eclipsed by, “there is nothing more we can do.”
Meet The Researcher: Dr. Rayne Rouce
To commemorate Black History Month, LLS is highlighting exceptional clinicians and healthcare professionals throughout the month of February. Dr. Rayne Rouce is a physician at Texas Children's Cancer Center where she is a member of the Leukemia/Lymphoma/Bone Marrow Transplant/Stem Cell Transplant Program. Dr. Rouce is board certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics.
Practicing Self-Advocacy During My PTCL Journey
The LLS Blog invites Aaron, who was diagnosed with peripheral T-cell lymphoma (PTCL), to share his reflections on becoming a self-advocate throughout his cancer experience. Read his powerful first-hand account